본 연구는 바이오복지를 위한 바이오산업의 현황과 기술혁신을 위한 조세지원제도에 대하여 살펴보고 그에 따른 개선방안을 제시하고 있다. 바이오산업에서의 기술혁신은 경제 성장과 복지 확대의 선순환 구조를 구축할 수 있다. 정부는 미래성장 동력에 대한 집중적 지원제도를 통해 바이오산업분야에 대한 조세지원제도를 계속적으로 증가하고 있다. 이러한 현 상황에서 바이오산업의 현황과 기술혁신 조세지원제도에 살펴보고 그에 대한 개선안을 제시하였다는 점에서 본 연구의 의의가 있다고 할 수 있다. 본 연구에서는 바이오복지를 위한 바이오산업의 지원을 위한 조세지원제도에 대한 개선안을 제시하고 자 한다. 첫째, 연구개발비 세액공제에서 중소기업에서 중견기업으로 성장하는 중소기업에 대해 세액공제 액 감소에 대한 방지책을 마련하고 있는데 반해 중견기업이 대기업으로 성장하는 과정에서 연구개발비 세 액공제의 점진적 유예제도가 없는 실정이다. 중견기업이 중소기업보다 상대적으로 연구개발 투자가 큼에도 불구하고 세액공제 유예를 적용받지 못한다는 것은 중견기업의 대기업으로의 성장을 막는 요인이 될 수 있으며, 중견기업의 연구개발 투자 유인을 낮추는 요인으로 작용할 수 있다. 따라서 중견기업이 대기업으로 성장할 때도 세액공제에 대한 점진적 유예 제도를 두어야 한다고 생각한다. 둘째, 신성장동력·원천기술의 연구개발비 세액공제에서 현행세법에서 국내에 소재한 기관으로 한정하고 있는데, 바이오산업의 실정상 생산액의 50%이상이 수출에 해당하며 이러한 수출에 따른 안정성과 유효성 입증 절차를 위한 국외 소재 연구기관의 필요가 높은 상황에서 국외 소재 연구기관에 대한 세액공제를 인정하지 않는 것은 바이 오산업에 불리한 제도라 할 수 있다. 따라서 이러한 부분을 개선하여 국내외 소재 연구기관으로 확대하여야 할 것으로 생각된다. 본 연구의 개선안을 뒷받침 할 실증연구가 시행되지 않았다는 한계점이 있다. 이러한 부분을 보완한 후 속연구가 필요하다고 생각된다. 본 연구를 통해 바이오산업의 성장성을 높여 바이오복지가 더욱 증진되길 기대한다.

This study explores influencing factors for firms’ willingness to participate in open innovation. We identify commitment and trust, switching cost, and IT infrastructure as the key predecessors. The study further examines how these variables affect the firms’ participation in open innovation using datasets from the UK biotechnology industry.

Marine biotechnology is one of the promising frontier of scientific exploration and commercial utilization for the next century. Compared with the terrestrial environment, the oceans of the world remain largely unexplored and include a major portion of bio-resources. Using the tools of biotechnology, the vast and diverse marine resources can be applied to produce new products and foods. Marine biotechnology has the characteristics of pro-environment, saying energy, and intensive knowledge. Therefore, we can take advantage of the marine biotechnology industry under our situation with the poor natural resources. The study focuses on the current status and administrative supports on marine biotechnology industry for upgrading the economic value of output. The status of our marine biotechnology industry is beginning stage in the economic aspects. Manpower and the level of most technologies are weaker than the ones of the advanced countries. More investment and recruiting skilled specialists are necessary because the improvement of marine biotechnology is depend on the technology and scientists. This study suggests the ways of administrative supports for domestic marine biotechnology: Efficient information network and supporting system for the development of marine biotechnology should be interrelated with other technical and scientific fields; The government should provide sustainable fund for the long-term research project and the infrastructure in the marine biotechnology.

In conclusion, tremendous potential exists for the application of animal biotechnology to the beef industry, especially with the utilization of embryo cloning to produce genetically identical animals and genetic engineering to modify animal genomes to improve and /or create new phenotypes for many economically important traits. Research involving embryo cloning and genetic engineering of animals has been continuous now for over a decade, however inefficiencies in techniques have prevented large scale application. large numbers of identical cattle will some day be produced and producers will be utilizing transgenic cattle in their beef production programs.

In 2012, the world population exceeded 7 billion and the need to address food security has never been greater. Achieving food security won’t be easy considering the megatrends of growing population, greater affluence, and increasing urbanization. Not only are more people demanding more food, but they want greater variety, including meat, dairy, fruits and vegetables. While demand for food is growing, farmers’ ability to increase productivity is facing unprecedented challenges. Scarcity of water, energy, and land is expected to define food production in the coming decades. Agricultural practices will also need to protect biodiversity through increasing productivity without expanding into natural ecosystems. Further exacerbating the situation is a changing climate that has led to higher temperatures and erratic weather patterns in some areas. Each day farmers face the challenge of growing more from less - increasing yields while protecting the environment by using less water, land, and energy. Global Agricultural Biotechnology companies like Syngenta have addressed these challenges through innovation in research and development by looking at the grower’s challenges holistically, including land, technology, and the community. The presentation will cover general R&D activities in an agricultural biotechnology company, which may differ from those in academic research institutes. Product safety and environmental considerations are integral to industry’s R&D work. To make earlier and better-informed decisions on which active ingredients or traits to move forward, normally companies begin safety trials early in the development process, facilitating timely engagement with regulators and other key stakeholders. Also to complement in-house expertise and bring in novel technologies which may or may not be used in agribusiness, companies are actively seeking value-adding partnerships and collaborations to bring exciting new offers to the grower. Development of a GM crop through all those activities mentioned above is quite a costly and lengthy process. My presentation will describe a typical process required for developing a GM crop in an agricultural biotechnology company from early discovery to commercialization to the market, which may give you a different perspective from academic point of view.